“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ...
Attendees interested in learning more about CoSara products, including the TB and HPV tests on the Company's upcoming Co-Dx PCR platform, are encouraged to stop by at VIROCON 2025. CoSara will be ...
The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest ...
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for ...
When Mary-Claire King embarked on a painstaking 17-year-long hunt for a gene linked to breast cancer, she had no inkling that its discovery would be saving lives some three decades later. King, an ...
Oncoguard® Liver blood test delivers six times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care. These findings will be presented as late-breaking data ...
ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the ...
IT affects one in eight men, and so it seems logical to have a prostate cancer screening programme. And yet, in a pivotal ...
Gastric Cancer Diagnostics Market size was valued at US$ 3.5 Bn in 2024 and is projected to reach US$ 6.9 Bn by 2035, growing ...
Hosted on MSN
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback